

1 **Allele biased transcription factor binding across human brain**  
2 **regions gives mechanistic insight into eQTLs**

3  
4  
5 Belle A. Moyers<sup>1</sup>, Jacob M. Loupe<sup>1</sup>, Stephanie A. Felker<sup>1</sup>, James M.J. Lawlor<sup>1</sup>, Ashlyn G.  
6 Anderson<sup>1</sup>, Ivan Rodriguez-Nunez<sup>1</sup>, William E. Bunney<sup>2</sup>, Blynn G. Bunney<sup>2</sup>, Preston M.  
7 Cartagena<sup>2</sup>, Adolfo Sequeira<sup>2</sup>, Stanley J. Watson<sup>3</sup>, Huda Akil<sup>3</sup>, Eric M. Mendenhall<sup>1</sup>,  
8 Gregory M. Cooper<sup>1\*</sup>, Richard M. Myers<sup>1\*</sup>

9  
10 <sup>1</sup> HudsonAlpha Institute for Biotechnology, Huntsville AL, USA  
11 <sup>2</sup> Department of Psychiatry and Human Behavior, University of California, Irvine CA, USA  
12 <sup>3</sup> The Michigan Neuroscience Institute, University of Michigan, Ann Arbor MI, USA

13  
14 \*Corresponding Authors  
15 rmyers@hudsonalpha.org  
16 gcooper@hudsonalpha.org

17  
18

19 **Summary**

20 Transcription Factors (TFs) influence gene expression by facilitating or disrupting the  
21 formation of transcription initiation machinery at particular genomic loci. Because genomic  
22 localization of TFs is in part driven by TF recognition of DNA sequence, variation in TF  
23 binding sites can disrupt TF-DNA associations and affect gene regulation. To identify  
24 variants that impact TF binding in human brain tissues, we quantified allele bias for 93  
25 TFs analyzed with ChIP-seq experiments of multiple structural brain regions from two  
26 donors. Using graph genomes constructed from phased genomic sequence data, we  
27 compared ChIP-seq signal between alleles at heterozygous variants within each tissue  
28 sample from each donor. Comparison of results from different brain regions within donors  
29 and the same regions between donors provided measures of allele bias reproducibility.  
30 We identified thousands of DNA variants that show reproducible bias in ChIP-seq for at  
31 least one TF. We found that alleles that are rarer in the general population were more  
32 likely than common alleles to exhibit large biases, and more frequently led to reduced TF  
33 binding. Combining ChIP-seq with RNA-seq, we identified TF-allele interaction biases  
34 with RNA bias in a phased allele linked to 6,709 eQTL variants identified in GTEx data,  
35 3,309 of which were found in neural contexts. Our results provide insights into the effects  
36 of both common and rare variation on gene regulation in the brain. These findings can  
37 facilitate mechanistic understanding of cis-regulatory variation associated with biological  
38 traits, including disease.

39

40 **Introduction**

41 Gene expression changes occur in essentially every biological process, including the  
42 development of diseases (Emilsson et al. 2008; Lee and Young 2013) such as  
43 neurodegenerative (Bonham et al. 2019, 2022; Zhao 2023) and psychiatric conditions  
44 (Clifton et al. 2019; Mimmack et al. 2002; Huang et al. 2020). Transcription factors (TFs)  
45 and their association with DNA are crucial determinants of gene expression, so identifying  
46 factors that influence the association between TFs and DNA is key to understanding  
47 variation in gene expression. A wide variety of tools have been developed to identify and  
48 catalogue DNA sequence motifs to which TFs preferentially bind (Bailey et al. 2015;

49 Ghandi et al. 2016; Castro-Mondragon et al. 2022). While informative, these approaches  
50 are limited by the fact that a motif's presence is neither necessary nor sufficient for TF  
51 association (Dror et al. 2015), so the impact of DNA sequence changes on motifs is of  
52 limited utility.

53 An alternative approach is to leverage natural genetic diversity across and within humans,  
54 specifically heterozygous variants, and assay TF binding behavior. Tools have been  
55 developed to identify differential binding across multiple experiments to identify changes  
56 in TF binding (Lun and Smyth 2016), but these are complicated by technical and biological  
57 variation. Complicating this issue further is that reference allele bias is a known obstacle  
58 in mapping sequence reads, and this can inflate the false discovery rate in studies of  
59 allelic effects (Degner et al. 2009; Stevenson et al. 2013; Rozowsky et al. 2011; Smith et  
60 al. 2013; Hach et al. 2014). The use of graph structures to represent personalized  
61 genomes or pangenomes (Li et al. 2020; Paten et al. 2017) can reduce reference allele  
62 bias (Garrison et al. 2018; Martiniano et al. 2020; Chen et al. 2021).

63 A recent study probed allele-specific binding across hundreds of cell types with  
64 corrections for reference allele bias and aneuploid regions (Abramov et al. 2021). The  
65 majority of these datasets were derived from cancer cell lines, limiting their applicability  
66 to non-diseased human tissue, or in contexts relevant for specific disease states. Another  
67 recent study highlighted the viability of a similar approach in human tissue samples by  
68 identifying allele-specific loci with 15 assays in 4 human donors across 30 tissues,  
69 including ChIP-seq assays of histone marks and several TFs, including the CCCTC-  
70 binding factor CTCF (Rozowsky et al. 2023). This study found relationships between  
71 allele-specificity of ChIP-seq and gene expression, including identifying GTEx eQTLs that  
72 were allele-specific and those that were not. This highlights the value of identifying allele-  
73 biased binding among transcription factors for understanding gene regulation.

74 Here, we greatly expand upon previous work by performing allele-biased binding analysis  
75 for 1,004 (Loupe et al. 2023) TF-ChIP-seq datasets, spanning 93 distinct TFs, RNA  
76 polymerase II (POLR2), and 5 histone marks in tissue samples from 9 anatomically  
77 defined brain regions in multiple donors. We used the vg toolkit to assemble personalized  
78 genomes to overcome reference allele bias and demonstrated that this approach

79 improves the calling of allele-biased binding. We explored dynamics of allele frequency  
80 in the population with allele bias and the relationship between allele-biased binding and  
81 disruption of TF binding motifs. We determined the effects on gene expression by using  
82 RNA-seq reads to assess eQTLs in these donors, allowing a mechanistic exploration of  
83 eQTL data. Finally, we highlight interesting examples of allele-biased binding identified in  
84 our datasets.


85

## 86 **Results**

### 87 *Graph Genomes improve read mapping and reduce reference allele bias*

88 To study the impact of genetic variation on TF binding, we first performed linked-read  
89 sequencing (10x Genomics) to generate phased genomes and call variants for two  
90 donors (**Figure 1A**; see Methods). We built personalized graph genomes that use the vg  
91 toolkit (Garrison et al. 2018), as it has been shown that it can reduce problems of  
92 reference allele bias and has previously been used for detection of missing signal in  
93 histones (Groza et al. 2020) and the detection of allele-biased TF footprints (Ouyang and  
94 Boyle 2022). To measure the effectiveness of this approach on our datasets, we initially  
95 mapped a pilot set of 20 ChIP-seq datasets, 10 in each of the two donors, using both  
96 conventional mapping to the hg38 linear reference via bowtie2 and personalized graph-  
97 genome mapping via vg. We observed an average increase in read mapping of 1.24% of  
98 the total read pool when using personalized graph genomes (**Table 1**). Despite this small  
99 change in overall mapping, the use of graph genomes greatly reduced the degree of  
100 reference allele bias for variants identified as significantly biased using the two  
101 approaches (**Figure 1B**). Because rare alternate alleles tend to be deleterious and may  
102 show increased preference for the reference allele, we restricted to cases of  $MAF > 0.05$   
103 for this analysis. Using hg38, we identified 21,207 cases of significant TF-allele bias at  
104 the nominal  $p \leq 0.05$  level (binomial test), 76.9% of which favor the reference allele,  
105 compared to 17,823 cases of significant TF-allele bias using a graph genome, with 52.8%  
106 favoring the reference allele. The reference bias trend was also observed, though  
107 reduced, when considering all variants, including those with  $MAF \leq 0.05$  with bias  
108 (**Supplemental Figure 1**), as well as variants with at least six mapped reads whether or

109 not there was a nominally significant bias (**Supplemental Figure 2**). Thus, graph genome  
 110 alignments tend to reduce reference-alignment artifact contributions to observed allelic  
 111 biases.



bowtie aligned to the linear reference (red) compared to using the vg toolkit aligned to a personalized graph genome (blue). Allele bias is more balanced between the reference and alternate for personalized graph genomes. **C.** There is significant disagreement in the number and identity of variants found preferring the reference and alternate alleles between methods. Heatmap showing the number of TF-biased allele interactions found nonsignificant, significant for reference, and significant for alternate by bowtie and vg.

112

	Percent of reads Mapped			
	Donor 1		Donor 2	
	Linear	Graph	Linear	Graph
<b>Control</b>	99.48	99.95	99.47	99.95
<b>BCL11A, DLPFC</b>	86.88	91.61	90.69	93.23
<b>CREB1, CB</b>	98.54	99.37	98.65	98.24
<b>CTCF, OL</b>	94.99	96.97	94.72	96.15
<b>CTCF, SG</b>	96.24	97.70	96.30	96.86
<b>MEF2A, DLPFC</b>	97.21	98.47	96.83	97.22
<b>RAD21, ANCG</b>	96.64	98.04	97.62	97.60
<b>RAD21, HC</b>	95.80	97.46	96.77	96.97
<b>SP1, AMY</b>	94.35	96.49	93.37	95.15
<b>TBR1, DLPFC</b>	96.41	97.93	96.65	96.91

**Table 1.** Percentage of reads mapped generally increases using personalized genomes compared to linear genomes. For 20 ChIP-seq datasets, the percentage of reads which were mapped to the reference genome when using a linear genome (Linear) or a personalized graph genome (Graph) for donor 1 (left) and donor 2 (right). In most cases, vg maps a larger percentage of reads.

113

114 To determine how specific variants were classified by each method, we next created a  
115 heatmap of the number of variants classified as significant or nonsignificant with each

116 mapping method (**Figure 1C**), and which of the alleles—reference or alternate—they  
117 preferred. We found that, for TF-allele interactions identified as significant in both  
118 methods, the direction of effect is well-conserved between the two methods. However,  
119 we found 4,402 variants that were significant only when we used a graph-based  
120 approach, and 8,508 variants that were significant only when we used a linear reference.  
121 For these variants, we note that bowtie2's mapping produces a strong preference for  
122 predicting the reference allele as the preferred allele, with 7,961 of the 8,508 hg38-  
123 specific allele biased events favoring the reference. In contrast, vg shows a more  
124 balanced distribution of variants favoring the reference and alternate alleles (55.2%  
125 favoring reference). This is consistent with the problems of reference allele bias seen in  
126 **Figure 1B**. In addition, when the two methods disagree in their classification of a variant,  
127 vg tends to have a higher read depth at the location (**Supplemental Figure 3**), suggesting  
128 that improved mapping of reads with variants results in a change in the apparent  
129 significance of the variant. Together, these findings suggest that use of personalized  
130 genomes substantially improves both specificity and sensitivity for detection of TF-allele  
131 bias.

132

### 133 *Allele-biased binding is consistent across donors and tissues*

134 We subsequently measured TF allelic bias using only the graph genome approach,  
135 applying it to ChIP-seq data from 93 TFs, RNA Polymerase (POLR2A), and five histone  
136 marks in up to nine anatomically defined regions of the brain across two donors, for a  
137 total of 1,004 ChIP-seq datasets (Loupe et al. 2023). We used vg to map these ChIP-seq  
138 datasets and calculate allele bias for each dataset in each haplotype. We initially identified  
139 all allele bias at a nominal p-value  $\leq 0.05$  (binomial test). At that threshold, we found that  
140 of the nearly two million regions with heterozygous DNA sequence variation in each  
141 donor, roughly 7.5% were significantly biased for at least one ChIP-seq dataset (**Table**  
142 **2**); as expected, this largely reflects the fact that TF binding occurs at only a small fraction  
143 (7-10%) of genomic loci (Loupe et al. 2023). We note that, while 266,448 variants are  
144 heterozygous in both donors (13.8%-14.1% of all heterozygous sites in each donor), only  
145 5,954 heterozygous variants that showed significant bias in either donor are significantly

146 biased in both donors (4.1-4.2%). This points to a 3-fold depletion of shared TF-biased  
147 variation between our two donors, suggesting that selection reduces the frequency of  
148 such variation in the population ( $p \leq 2.2 \times 10^{-16}$ , binomial test).


	Donor 1	Donor 2	Shared (Significant in Both Donors)
Variant regions	3,032,858	3,074,271	809,297
Heterozygous regions	1,894,277	1,932,258	266,488
Significantly Biased ( $p \leq 0.05$ )	139,234	144,952	28,751 (5,862; 20.4%)
Significantly Biased ( $p \leq 0.001$ )	4,328	3,876	486 (142; 29.2%)
Significantly Biased when summed across tissues ( $p \leq 0.001$ )	7,828	9,570	1,195 (377; 31.5%)

**Table 2.** The number of variants found significant in each donor individual, as well as the shared set of variants. When parentheses are present, the number outside of the parentheses denotes the number of variants found significant in at least one of the two donors, while the number inside the parentheses shows the number which were significant in both donors. Percentages denote the percent of this intersect (within parentheses) compared to the union (outside of the parentheses).

149  
150 We next assessed reproducibility. Given that we performed experiments in tissues from  
151 multiple brain regions within each donor and two donors for each, we assessed  
152 consistency of results both on the same region between the two donors and between  
153 different regions within the same donor. Each comparison type captures a different  
154 mixture of technical and biological factors. Cross-donor/within-region differences may be  
155 due to either experimental errors or genuine between-donor differences, while cross-

156 region/within-donor differences may be due to experimental errors or genuine region-level  
157 differences.

158 We first assessed between-donor reproducibility of the effects of shared variants by  
159 determining whether or not the variant was consistent in its effect direction between the  
160 two donors. For each shared variant (i.e., both donors are heterozygous) that was  
161 significant in at least one donor for a given TF in a given region, we determined the  
162 number of reads mapping to each allele in both donors (restricting to cases with at least  
163 six total reads mapped) and determined whether or not the same allele is favored in both  
164 donors. We measured effect direction reproducibility as 100% minus twice the percentage  
165 of inconsistent effect direction observations, as half of all random comparisons would by  
166 chance appear to be consistent (i.e., if 10% of comparisons exhibit inconsistent effect  
167 directions, the inferred reproducibility rate is 80%). We then assessed reproducibility  
168 across a range of nominal bias p-value thresholds (**Figure 2A**). We found that at a p-  
169 value cutoff of 0.05, just under 60% of variant effects on TF binding are inferred to be  
170 reproducible across donors, but that at a cutoff of 0.001 that increases to more than 85%  
171 of the variants.



**Figure 2.** Reproducibility and concordance of TF-allele bias within and between donors.

**A.** Between-donor reproducibility. The fraction of TF-allele bias cases which were reproducible in the comparable TF-allele interaction in the same tissue across donors (y-axis) as a function of the minimum p-value cutoff used for significance (x-axis). Reproducibility was defined as  $1 - 2 \times (\text{Percent of inconsistent directional effects identified})$ . **B.** Within-donor reproducibility. The fraction of TF-allele bias cases which were reproducible when comparing the same TF-allele interaction across different tissue contexts within the same donor. Reproducibility was defined as in 2A. **C.** Correlation of  $-\log(p\text{-value})$  of effects of a variant across tissues, for variants with a pvalue of  $\leq 0.001$  in at least one tissue for factors with ChIP-seq datasets in all 9 tissues. Bottom shows dot-plots of variant effects. Top shows correlation coefficients (Pearson) between each tissue. Diagonal line notes each tissue. Abbreviations denote: dorsolateral prefrontal cortex (DLPFC), frontal pole (FP), occipital lobe (OL), cerebellum (CB), anterior cingulate (AnCg), subgenual cingulate (SCg), dorsomedial prefrontal cortex (DMPFC), amygdala (Amy), and hippocampus (HC).

172

173 We also explored within-donor reproducibility between regions. This analysis yielded far  
174 more comparisons, as all heterozygous variants are shared across all regions within the  
175 same donor, and each TF could be compared across up to nine brain regions, resulting  
176 in up to 36 total comparisons for each variant's impact on TF binding. We therefore  
177 assessed within-donor reproducibility in the following way. We determined all variants that  
178 impacted a TF's binding in at least one brain region. We then looked in each brain region  
179 where data were available for that TF with at least six total mapped reads and counted  
180 the number of reads mapping to each allele. We then determined reproducibility as  
181 described above, at each p-value cutoff. We found that at a p-value cutoff of 0.05,  
182 reproducibility is only marginal at >30%, but that a p-value cutoff of 0.001 between-region  
183 reproducibility was more than 80% (**Figure 2B**).

184 Based on these observations, we restricted further analyses of significant variants to  
185 those with a nominal p-value  $\leq 0.001$  for a reproducibility rate of >80% unless otherwise  
186 noted. This metric confidently identifies allele-biased TF-DNA interactions both within and  
187 across donors. A summary of the number of variants impacting TF binding at this cutoff  
188 is included in **Table 2**.

189 Because within-donor reproducibility was high, we assessed the overall correlation across  
190 brain regions simultaneously for TF-DNA interactions. The ChIP-seq datasets we  
191 analyzed fall into two categories, four large brain regions (cerebellum, dorsolateral  
192 prefrontal cortex, occipital lobe and frontal pole), which provided enough material to do  
193 ChIP-seq on 93 TFs, and five smaller brain regions, which provided enough material for  
194 only 16 TF ChIP-seq maps. For each pairwise comparison of brain regions, we  
195 determined the correlation of the  $-\log_{10}(p\text{value})$  for each TF-DNA biased interaction we  
196 identified (**Figure 2C**). We note that correlations between tissues range between 0.70  
197 and 0.91 (Pearson's correlation coefficient) when using TFs with ChIP-seq data ( $n=16$ ) in  
198 all nine brain regions, and 0.81-0.91 when using a larger number of TFs ( $n=93$ ) limited to  
199 four brain regions (**Supplemental Figure 4**). The cerebellum showed good but  
200 comparatively lower correlation with other tissues. This is expected, as the cerebellum  
201 has markedly different cellular makeup than other brain regions (Andersen et al. 1992;

202 Loupe et al. 2023). Overall, this analysis shows a strong quantitative correlation for TF-  
203 variant bias across multiple regions of the brain.

204 Because variants have strong reproducibility across and within donors and have high  
205 correlation in their effect size of impact upon TF association within donors, we combined  
206 reads across all brain regions for each variant for a given ChIP-seq target for other  
207 downstream analyses (**Table 2**). Given the extra statistical power from combining reads,  
208 we observed a 2-fold increase in the identified TF-biased variants at  $p \leq 0.001$ : 7,828 TF-  
209 biased variants (0.41%) in Donor 1 and 9,570 (0.50%) in Donor 2 (at  $p \leq 0.001$ ). Among  
210 these variants, we asked how many showed corroborating bias in POLR2A or any of the  
211 histone datasets, which would not be predicted to be directly altered by variants, but are  
212 likely to reflect altered gene regulation at that variant. We identified those variants that  
213 were also biased for at least one histone mark or POLR2A, and found that approximately  
214 half are biased for at least one of these datasets (4,271 in donor 1 and 4,734 in donor 2).  
215 We found that, for such variants, more TFs are generally biased for the variant  
216 (**Supplemental Figure 5**), and that the significance of TF bias increases (**Supplemental**  
217 **Figure 6**).


218 **Supplemental Tables 1 and 2** show all nominally significant ( $p \leq 0.05$ ) heterozygous  
219 regions for any ChIP-seq target or input DNA in each donor based upon summed reads  
220 across brain regions as well as relevant information about each variant. Hereafter, we  
221 consider only those variants that impact TF binding, independent of POL2RA or histone  
222 effects, at  $p \leq 0.001$ .

223

224 *Allele Bias is prevalent in functional regions important for neuronal differentiation*

225 We next explored the genomic properties of the 17,309 unique variants that impact TF  
226 binding using candidate Cis-Regulatory Elements (cCREs) from the ENCODE  
227 Consortium (Luo et al. 2020), which marks elements such as promoters and enhancers.  
228 We classified each heterozygous region, TF ChIP-seq peak, and allele-biased variant into  
229 cCRE categories (**Figure 3A**). Not surprisingly, we found that ChIP-seq peaks  
230 overwhelmingly lie within cCRE regions, while the majority of heterozygous variation falls  
231 outside of cCRE regions. However, most cases (73.3%) of TF-allele bias fall within or

232 near cCREs, despite requiring only a minimum of 11 reads total across all experiments  
233 to potentially be found as significantly biased at  $p \leq 0.001$  for a given variant. Despite  
234 being overwhelmingly within cCREs, 83.2% of allele-biased variants are not in a called  
235 peak for that TF.



**Figure 3.** Genetic and genomic properties of variants displaying TF-allele bias. **A.** Stacked barplots showing the fraction of regions which have overlap with a particular cCRE type for all variant haplotypes (first from top), all TF peaks (second from top), haplotypes found significant for at least one TF (second from bottom), and haplotypes found significant in at least one TF while also overlapping with a TF peak (bottom) (y-axis). Cumulative fraction is shown on the x-axis. Barplots are colored by cCRE type as PLS (promoter-like signal): red, pELS (proximal enhancer-like signal) orange, dELS (distal enhancer-like signal) yellow, CA-CTCF (chromatin-accessible CTCF signal) pink, CA-TF (chromatin-accessible, TF signal) blue, TF (TF signal) blue-green, CA (chromatin-

accessible) green, and with non-cCRE regions plotted in grey. **B.** Variants which are either very rare or very common in the population show highly significant allele bias. For varying ranges of derived allele frequency (x-axis), we show the fraction of significant variants which were found at or below a given significance threshold (y-axis). **C.** For very low-frequency derived alleles, a volcano-like plot is shown which relates the ChIP-seq preference for the ancestral allele (x-axis,  $\log(\text{ancestral ChIP-seq reads}+1 / \text{derived ChIP-seq reads}+1)$ ) and the significance (y-axis,  $-\log_{10}(\text{pvalue})$ ) as determined by a binomial test) for each significantly-biased variant. Points are colored by their derived allele frequency, with rarer derived alleles being black and more common, up to DAF=0.001, being plotted in yellow. For very rare alleles, there is a stronger preference for the ancestral allele, and the significance of bias is higher. **D.** For variants which weaken or strengthen a JASPAR motif (i.e. a motif was found in each sequence, but the score changed) for one of our assays TFs, the difference in FIMO score between the ancestral and derived allele (y-axis) versus the  $\log(\text{ancestralReads}/\text{derivedReads})$  for the relevant TF. Spearman's Rho = 0.658,  $p \leq 2 \times 10^{-16}$ .

236

237 Restricting to only those cases of allele-biased binding within peaks, we found that,  
238 relative to global peak locations, allele-biased binding is 1.8-fold enriched for PLS regions  
239 ( $p \leq 2.2 \times 10^{-16}$ , binomial test). We also found that a substantial number of biased variants  
240 occur in dELS and pELS regions, consistent with noted trends in the evolution of variability  
241 in enhancer function over evolutionary time (Rebeiz and Tsiantis 2017; Lynch et al. 2015;  
242 Emera et al. 2016).

243 To explore the function of these regions, we performed GO analysis using GREAT  
244 (McLean et al. 2010; Gu and Hübschmann 2023), using allele-biased regions as our  
245 regions of interest and all peak regions minus allele-biased regions as controls  
**(Supplemental Table 3).** We note that the top 10 enriched terms (sorted by adjusted  
246 hypergeometric p-value) are largely involved in neural development, organismal  
247 development, and cell communication.

249

250 *Very rare variants are more likely to disrupt TF-DNA associations*

251 Because allele-biased regions are found near neural and developmental genes,  
252 suggesting a functional outcome on cellular and developmental phenotypes, we explored  
253 how common these variants are in population databases. We hypothesized that any

254 derived allele which significantly altered the expression of a key neural or developmental  
255 gene would experience natural selection during human evolution. We identified ancestral  
256 alleles via comparative genomics among apes using Ensembl (Cunningham et al. 2022)  
257 and used gnomAD (Chen et al. 2022) to identify current allele frequency in the human  
258 population. We then binned TF-biased variants by derived allele frequency and noted the  
259 fraction in each bin with a given allele bias p-value (**Figure 3B**). We found that, for rare  
260 variation in the population (extreme right and left derived allele frequency bins), bias tends  
261 to be more significant than for common variation (middle bins). However, we note that  
262 there are relatively few allele-biased variants that are rare in the population but for which  
263 the derived allele is more common (e.g., 41 variants with DAF >0.999, vs 719 with DAF  
264 < 0.001).

265 To further analyze effects of the ancestral and derived alleles among rare variants, we  
266 selected the TF-biased variants with derived allele frequency (DAF) of 0.001 or lower (791  
267 variants) and determined the number of reads that map to the ancestral and derived  
268 alleles (**Figure 3C**). We found a strong preference for the ancestral allele both in the  
269 number of cases supporting it (70.2% support ancestral versus 29.8% derived), and  
270 degree of bias significance (**Figure 3C**). When restricting to variants with very high DAF  
271 ( $\geq 0.999$ ) (41 variants), we observed the opposite bias (33.7% support ancestral, 66.3%  
272 support derived), (**Supplementary Figure 7**). Among variation with DAF between 0.001  
273 and 0.999 (i.e., sites at which both alleles are frequently observed in the human  
274 population, 24,818 variants), there is much reduced ancestral versus derived bias (56.2%  
275 vs 43.8%, **Supplemental Figure 8**). This suggests that common alleles are  
276 approximately equally likely to increase or decrease TF-DNA associations, whereas rare  
277 alleles are more likely to specifically disrupt TF-DNA association, while a smaller fraction  
278 appear to lead to new TF-DNA associations.

279 To evaluate the mechanism of allele-biased variation on TF-binding, we identified motifs  
280 that are disrupted by a heterozygous variant using human motifs for relevant TFs in the  
281 JASPAR database (Castro-Mondragon et al. 2022), and the fimo function of the meme  
282 (Bailey et al. 2015) suite. We first checked, for each TF, each biased variant and asked  
283 what percentage of the time the motif for that TF was significantly disrupted from  
284 consensus. We found a wide range for this metric, with 0-44% of the biased loci showing

285 disrupted motifs. This likely reflects each TF's motif strength. For example, the zinc finger  
286 factor CTCF, which has a long 14 bp consensus motif with many highly conserved bases,  
287 had its motif disrupted at 44% of the loci showing bias for that factor. By comparison,  
288 MAZ, which has a 7 bp motif with no strongly conserved nucleotides, had a disrupted  
289 motif in only 9.5% of TF-biased loci (**Supplemental Figure 9, Supplemental Table 4**).  
290 We next identified cases where a motif's score changed between the two alleles and  
291 determined whether the derived or ancestral allele had a higher score, and the number  
292 of reads mapping to each allele. We found that allelic disruption of a motif is moderately  
293 correlated (Spearman's Rho = 0.658) with TF ChIP-seq reads mapped (**Figure 3D**). This  
294 is also true of variants that entirely remove or create a motif, defined as finding a fimo hit  
295 in one allele and none at all in the other (**Supplemental Figure 10**) (Spearman's Rho =  
296 0.494).

297 Because we observed these trends in enrichment and in motif modifications, we then  
298 determined whether or not there was evidence for enrichment or depletion of sites with  
299 TF-biased variation being under purifying selection throughout mammalian evolution. We  
300 used the Genomic Evolutionary Rate Profiling (GERP) (Davydov et al. 2010) metric and  
301 identified those variants with GERP>4, a commonly-used cutoff for selective constraint  
302 (Schubert et al. 2014; Marsden et al. 2016). For each TF, we identified all variant locations  
303 with at least 11 reads mapped (minimum number of reads for binomial significance of  
304 0.001), and determined the number of variants with GERP>4 and with GERP<4 for  
305 variants that were significant and for those that were non-significant. (**Supplemental**  
306 **Figure 11**). We find that, while most TFs have an apparent depletion of biased variants  
307 under selective constraint, none are significantly depleted (Chi-squared test).

308


### 309 *Allele-biased binding offers insight into eQTL mechanisms*

310 Because TFs regulate the expression of RNA, we explored the relationship between  
311 allele-biased binding and the GTEx (GTEx Consortium 2020) database of expression  
312 quantitative trait loci (eQTLs) (Nica and Dermitzakis 2013). We found that 51.98% of all  
313 significant GTEx variants were present in at least one of our donors in either a  
314 heterozygous or homozygous state. We found 1,142,111 variants in a heterozygous state

315 in Donor 1, and 1,123,497 in Donor 2, a necessary condition for detecting allele-biased  
316 binding of TFs. Of these variants, we found significant TF-allele bias in 7,459 variants in  
317 Donor 1 and 7,975 in Donor 2 for a total of 14,419 unique variants. We found that the  
318 involvement of allele-bias for individual TFs in GTEx eQTLs is similar to the genome at  
319 large (**Supplemental Figures 9 and 12**).

320 We next explored RNA-seq allele bias by mapping total RNA-seq reads to personalized  
321 genomes, determining the number of reads preferring each allele, summing across  
322 tissues, and identifying variants with a bias p-value  $\leq 0.001$ . Using a model of known  
323 genes in the hg38 build (Bioconductor Core Team 2017), we determined which of these  
324 cases of allele bias overlapped with known genes. In Donor 1, 80.86% (5,850 of 7,191  
325 total) of allele-biased RNA reads occurred in known gene models, and 81.35% (5,774 of  
326 7,141 total) in Donor 2. We detected allele-biased expression in 10.16% of gene bodies  
327 in Donor 1 and 11.32% in Donor 2, consistent with estimates of the fraction of genes with  
328 allele-biased expression in earlier studies (Gimelbrant et al. 2007; Kravitz et al. 2023).


329 We next identified variants in eQTLs that displayed both TF-allele bias as well as in-phase  
330 allele-biased RNA expression within the appropriate gene body as noted in GTEx. We  
331 found 6,709 GTEx variants that existed in a heterozygous state in one or both of our  
332 donors and with both a ChIP-seq allele bias and an in-phase heterozygous variant in the  
333 appropriate gene body with an RNA-seq allele bias. Because eQTLs can be tissue-  
334 specific (Mizuno and Okada 2019), we restricted to GTEx variants with annotations in  
335 neural tissue for further investigation. We found 3,309 of these variants were identified in  
336 the brain or neural tissue by GTEx. For each of these 3,309 variants, we identified the  
337 predicted slope of the variant for a given gene as well as the degree and direction of  
338 observed RNA-seq allele bias in our reads. We found a modest, but highly significant,  
339 correlation of 0.43 (Spearman's Rho,  $p \leq 2.2 \times 10^{-16}$ ) (**Figure 4A**). This suggests a  
340 mechanistic link between allele-biased TF binding and RNA expression, consistent with  
341 the general function of TFs, that at least partially explains population-wide genetically-  
342 determined expression variation.



343

344 We highlight a simple case found in Donor 2, chr5\_150449748\_G\_A\_b38, in **Figure 4B-D**. The variant occurs near the TSS of the *RPS14* gene (**Figure 4B**), which encodes a  
 345 ribosomal protein. This eQTL was found to be significant in 10 tissue contexts in GTEx,  
 346 with slope values from -0.27 to -0.11, meaning that the alternate allele decreases  
 347 expression relative to the reference allele. We found that RNA expression in our dataset  
 348 is biased in the expected direction (**Figure 4C, left**), and that there is TF-allele bias over  
 349 the variant for the MAZ transcription factor (**Figure 4C, right**). Comparing the two  
 350 sequences, we find that the alternate variant disrupts the MA1522.1 motif of the MAZ  
 351 (**Figure 4D**).

353 In another case, we explored a more complicated eQTL case found in a heterozygous  
354 state in both donors, chr22\_32474782\_C\_T\_b38, in **Figure 5**. This variant occurs in the  
355 promoter region of *FBXO7* (**Figure 5A**), an F-Box protein with a suggested role in  
356 Parkinson's Disease (Joseph et al. 2018; Conedera et al. 2016; Burchell et al. 2013). We  
357 found that Hi-C data from iCell GlutaNeurons (Rogers et al. 2023) supports this locus  
358 interacting with several distal regions (**Figure 5A**). This variant was found in an eQTL for  
359 *FBXO7* expression in eight tissues with slope values from 0.2 to .45. We found that our  
360 RNA-allele bias data also supports the alternate allele having a higher expression (**Figure**  
361 **5B, left**), and that several TFs in each donor also prefer the alternate allele (**Figure 5B,**  
362 **right**). Interestingly, this variant is also found to be associated in GTEx with a tissue-  
363 dependent change of expression of the *SYN3* gene, a neuronal phosphoprotein that  
364 associates with the surface of synaptic vesicles. We had limited ability to detect such  
365 changes, with only a single heterozygous RNA-biased variant in Donor 2 in phase with  
366 the eQTL variant, but found a strong preference for expression of the *SYN3* reference  
367 allele. The fact that this variant occurs in a known CTCF binding motif (MA0139.1) (**Figure**  
368 **5C**) and shows TF-allele bias for cohesion factors (**Figure 5B, right**) suggests some  
369 measure of distal action for this variant consistent with CTCF's known roles (Splinter et  
370 al. 2006). We also observed several other phased variants were present in our donors in  
371 this region, each for the *FBXO7* gene. We explored allele-biased binding at these variants  
372 and highlight our findings in **Table 3**. Of note, several of these variants show no bias for  
373 any of our tested transcription factors or histone marks. This suggests that allele-biased  
374 binding may be a method of fine-mapping eQTLs when data are available.



375

GTEx Variant	Donor 1 Presence	Donor 2 Presence	Donor 1 Significant ChIP-seq	Donor 2 Significant ChIP-seq
chr22_32470947_T_C_b38	Yes	Yes	None	None
chr22_32471256_A_T_b38	No	Yes	NA	None
chr22_32471173_G_C_b38	Yes	Yes	None	None
chr22_32471541_G_A_b38	Yes	Yes	None	None

chr22_32473024_C_T_b38	Yes	Yes	None	None
chr22_32473508_G_T_b38	Yes	Yes	CTCF	CTCF
chr22_32474674_C_T_b38	Yes	Yes	None	POL2, ATF7, H3K9AC
chr22_32474782_C_T_b38*	Yes	Yes	CTCF, H3K27AC, NEUROD1, NR2F2, RAD21, ASH2L, CC2D1A, H3K9AC, NONO, TRIM28	CTCF, H3K4ME3, POL2, RAD21, SOX8, SP1, ATF7, H3K9AC, ZBTB7B
chr22_32474819_C_T_b38**	No	Yes	NA	

**Table 3.** For variants found in GTEx which were in-phase with the focal variant, chr22\_32474782\_C\_T\_b38 (marked with \*, explored in Figure 5), we show whether or not the variant was present in each of the two donors, as well as note any TF with significant allele-biased binding for that variant. We note that chr22\_32474819\_C\_T\_b38 (marked with \*\*) was found within 100bp of the focal eQTL in donor 2, and so was analyzed in conjunction with the focal eQTL (see methods).

376

## 377 **Discussion**

378 Here, we present an analysis of allele-biased binding across 93 transcription factors,  
379 identifying thousands of variants that show biased binding. We identified a threshold for  
380 reproducibility that provides confidence to our calls both within a single donor and across  
381 multiple donors, controlling for a wide variety of biological and technical variables. By  
382 linking to allele-biased expression of nearby genes, we also relate variation that impacts  
383 TF binding directly to effects on gene regulation .

384 We found that TF-biased variants are prevalent in distal and proximal enhancer regions  
385 as well as in promoter regions. This highlights that these variants occur in regions known  
386 to play major roles in gene expression. This, combined with the many cases of allele-  
387 biased binding within eQTLs, shows a potential mechanism of eQTLs, and may lead to  
388 insights of disease mechanisms (Musunuru et al. 2010). Because a majority (>80%) of  
389 the allele-biased variants fall outside of called peaks for the biased TFs, this also stresses  
390 the importance of TF binding outside of peaks that have measurable impact, as noted in  
391 previous studies (Lun and Smyth 2016; Hiatt et al. 2023).

392 We found that rare variation (MAF < 0.1%) is enriched, relative to common variation, for  
393 TF-binding impacts (**Figure 3B**), suggesting that there was purifying selection against  
394 such variation in general. For common variants that do impact binding, neither the  
395 ancestral nor derived alleles tend to be favored (**Supplemental Figure 7**). In contrast,  
396 among rare variants (MAF < 0.1%), there is a bias in favor of common alleles over rare  
397 alleles, whether the common allele is derived or ancestral. This suggests that new  
398 mutations more often disrupt, rather than enhance, TF binding. Still, the fact that TF-  
399 variant bias can sometimes prefer the novel allele even in rare variants is consistent with  
400 models of *de novo* motif formation and gene birth (Behrens and Vingron 2010; Schlötterer  
401 2015; Carvunis et al. 2012; Iyengar and Bornberg-Bauer 2023; Ruiz-Orera et al. 2015;  
402 Papadopoulos et al. 2021), which have suggested that few changes need to be made to  
403 a given sequence to form a novel TF motif, and that this formation plays a crucial role in  
404 sampling of transcriptional regulatory space. This is emphasized by the fact that we  
405 observe a small subset of derived alleles that have become common in the population  
406 (DAF $\geq$ 0.999), and are favored by TFs (**Supplemental Figure 7**).

407 As has been previously observed (Abramov et al. 2021), in cases of TF-biased variants,  
408 there is a general preference for a given TF to favor the allele with a stronger presence  
409 of its motif, and TF read-depth measurements confirm a correlation between the degree  
410 of motif disruption and total read-depth for variants within motifs (**Figure 3D**). Beyond  
411 demonstrating the general nature of this phenomenon, it can be combined with known  
412 eQTLs in our dataset to facilitate fine-mapping and mechanistic hypothesis generation.  
413 For example, we highlight a case of a variant in an eQTL that displays allele biased  
414 binding in our dataset and specifically disrupts a motif for that TF (**Figure 5**), affecting

415 regulation of a gene that is relevant to neurodegenerative and neuropsychiatric traits. The  
416 results from this analysis yielded TF-biased variation linked to 9,748 GTEx eQTLs,  
417 providing a rich resource for future fine-mapping efforts.

418 We also found that many sites of allele-biased binding represent coordinated multi-factor  
419 effects. For example, 48.1% of sites that associate with altered binding of one TF  
420 influence binding of one or more additional TFs (**Supplemental Tables 1-2**). Similarly,  
421 approximately half of variants with TF-binding bias also have altered histone marks and  
422 POL2 binding, consistent with the expected relationships between TF binding and general  
423 recruitment of transcriptional machinery. Finally, we found that approximately 30% of TF-  
424 allele-biased variants in our data impacted cohesion complex members (**Supplemental**  
425 **Figure 9**). This suggests that genetic variants which alter three-dimensional genome  
426 interactions are a major contributor to gene expression variation in the population.

427 Overall, our study provides a resource of allele-biased variants that are experimentally  
428 validated to impact TF binding in a biologically relevant context. These results will further  
429 our understanding of how alteration in DNA sequence translates to changes in biological  
430 function, particularly in relation to analyses of gene regulation in the human brain.

431

## 432 **Methods**

### 433 *Whole Genome Sequencing and variant calling*

434 We extracted high molecular weight DNA from approximately 20 mg cortex tissue from  
435 each donor using the MagAttract HMW DNA kit (Qiagen 67563). We prepared linked  
436 read libraries using the Chromium Genome Reagent Kit v2 following the protocol provided  
437 by 10x Genomics. We processed sequence reads using the longranger software suite  
438 from 10x Genomics. We identified variants by aligning to a 10x Genomics-provided,  
439 longranger-enabled hg38 reference (version 2.1.0) using longranger wgs v2.2.2. We  
440 called variants using GATK 3.8-1-0-gf15c1c3ef via the –vcmode gatk option in the  
441 longranger wgs workflow (Loupe et al. 2023).

442

### 443 *Genome Construction*

444 We constructed graph genomes using the vg toolkit version 1.20, available at  
445 <https://github.com/vgteam/vg> (Garrison et al. 2018). The “construct” command was used  
446 with the hg38 genome and all phased variants which passed quality metrics. We then  
447 pruned the graph using the “prune” command with default parameters. We produced the  
448 gbwt index using the “index” command with default parameters, and the gcsa index was  
449 created using the parameters: -X 3 -Z 4000 -p -k 11.

450 We also constructed linear FASTA sequences for comparisons of linear and graph  
451 genome reference allele bias. We identified variants which were within 1 full read length  
452 (100 bp) of one another, and on the same phase. We identified regions based on such  
453 nearby, in-phase variants, and constructed a fasta file containing, for each such region,  
454 one entry for either haplotype. In these haplotypes, 78.6% of regions contain only a single  
455 variant, while 96.2% had no more than 2 variants.

456

457 *RNA-seq*

458 We performed RNA-seq for each of the nine brain regions as outlined in Loupe *et al.*  
459 2023.

460

461 *ChIP-seq experiments*

462 We performed ChIP-seq experiments with 93 TFs and five histone marks in nine distinct  
463 brain regions, for a total of 1,028 experiments. Full methods for production of ChIP-seq  
464 reads are presented in (Loupe *et al.* 2023).

465

466 *Peak Calling*

467 We called peaks according to the ENCODE Consortium’s standard pipeline, using  
468 experiments from donors as replicates, as described in (Loupe *et al.* 2023).

469

470 *Read Mapping and processing*

471 For traditional read mapping, we used bowtie2 (Langmead and Salzberg 2012) with  
472 default settings to map to the human hg38 genome.

473 For graph genome mapping, we used the vg map command with arguments -A -K -M 3.  
474 The vg surject command was used to create sam and bam file formats for determining  
475 allele bias. The samtools package (Danecek et al. 2021) was used for sorting and filtering  
476 by quality. Picard was used for filtering duplicates.

477 Once reads were mapped and filtered, we identified and separated out only those reads  
478 that overlapped with a heterozygous variant using custom R code. In brief, for a read  
479 mapped to a heterozygous region, we determined the minimum string distance, i.e.  
480 greatest sequence similarity, between the read and each of the two haplotypes, and  
481 assigned the read to the haplotype that was most similar to the read's sequence. In cases  
482 where the minimum string distance between the two haplotypes was equal, we assigned  
483 half a read to each sequence, leading to a more conservative binomial test for allelic bias.

484

#### 485 *Identification of Allele Bias*

486 For a given ChIP-seq or RNA-seq dataset, after mapping, we identified those  
487 heterozygous regions with at least six total reads (the minimum number of reads for a  
488 binomial test to be nominally significant at  $p \leq 0.05$  if all reads map to a single haplotype).  
489 After assigning a number of reads to each haplotype, we performed a two-sided binomial  
490 test for each haplotype for each ChIP-seq dataset.

491 After assessing the consistency of allelic biases across brain regions and donors, we  
492 summed the number of reads assigned to each haplotype for a given TF across all tested  
493 brain regions within a single donor, and a two-sided binomial test was performed for each  
494 haplotype for each TF with at least six reads when combined across tissue samples, the  
495 minimum number of reads required for a significant binomial test p-value at a 0.05 cutoff.  
496 For some analyses, we restricted to cases of at least 11 reads total, the minimum number  
497 of reads required for a significant binomial test p-value at a 0.001 cutoff. In all analyses,  
498 we removed variants that showed apparent allele bias in control input DNA for the

499 summed dataset in the respective donor. These variants are included in **Supplemental**  
500 **Tables 1 and 2.**

501

502 *VEP Annotations and Derived Allele Frequency*

503 We annotated vcf files using the following command:

504

505 `vep -i 5397-JL-0002_phased_variants.vcf.gz --config vep108.ini --vcf -o 5397-JL-0002_annotated.vcf.gz`

506

507 The config file is provided in the Supplemental\_Code.zip file as vep108.ini. VEP engine  
508 and cache version 108 (McLaren et al. 2016) was used with a GRCH38 fasta file. We  
509 used a merged transcript set of Ensemble (Cunningham et al. 2022) and RefSeq (O’Leary  
510 et al. 2016). Custom annotations were Gnomad (Chen et al. 2022) allele frequency using  
511 v 3.1.1, Bravo topmed allele frequency freeze 8 (Taliun et al. 2021), GRCh38 GERP  
512 scores (as distributed with CADD v1.6), and CADD v1.6 scores (Rentzsch et al. 2019).

513 We treated each variant in the haplotype separately in the rare cases where a single  
514 haplotype region contained multiple variants with different Derived Allele Frequencies and  
515 that haplotype region showed TF binding bias.,

516

517 *GTEx Data and identification of RNA allele bias*

518 We downloaded GTEx variants on June 30<sup>th</sup>, 2023 from  
519 [https://storage.googleapis.com/gtex\\_analysis\\_v8/single\\_tissue\\_qtl\\_data/GTEx\\_Analysis\\_v8\\_eQTL.tar](https://storage.googleapis.com/gtex_analysis_v8/single_tissue_qtl_data/GTEx_Analysis_v8_eQTL.tar)

521 For a given eQTL variant in our data, we determined whether or not there was a phased  
522 heterozygous variant within the appropriate gene body in our data, as this was necessary  
523 for physically linking the TF-allelic bias to RNA allelic bias. In such cases, we determined  
524 the variant in the gene body which was on the same allele as each of the two haplotypes  
525 of the heterozygous variant in the GTEx dataset. We calculated significant bias as  
526 discussed above, and we calculated effect size as:

527 
$$RNA\ bias = -\log\left(\frac{alternate\ allele\ reads + 1}{reference\ allele\ reads + 1}\right)$$

528

529 *GREAT Gene Ontology Analysis*

530 We performed GREAT analysis using the rGREAT (v2.1.8) package  
531 (<https://www.bioconductor.org/packages/release/bioc/html/rGREAT.html>) (Gu and  
532 Hübschmann 2023). We associated genomic ranges with genes using the basal plus  
533 extension method (5kb upstream, 1kb downstream, 500kb max extension). We calculated  
534 enrichment for GO Biological Process terms within GREAT with background regions set  
535 as the union of all ChIP-seq peaks with heterozygous variation that did not show evidence  
536 of allele-biased binding.

537

538 *Data Analysis*

539 We performed data analysis using R version and 4.1.0 (2010), as noted in appropriate  
540 scripts.

541

542 *cCRE catalog*

543 We downloaded the V4 cCRE human dataset from the ENCODE Portal under accession  
544 ENCSR800VNX.

545

546 **Data Access**

547 All code used for these analyses is available via GitHub at  
548 [https://github.com/bmoyers/BrainTF\\_Allele\\_Biased\\_Binding](https://github.com/bmoyers/BrainTF_Allele_Biased_Binding), and is also supplied as  
549 Supplemental\_Code.zip. These data and the accompanying analyses will serve as a  
550 resource to understand genome regulation in psychiatric diseases and are publicly  
551 available through the PsychENCODE Consortium and available for download at the  
552 following link: <https://doi.org/10.7303/syn4921369>.

553

554 **Competing Interest Statement**

555 We have no competing interests to disclose.

556

557 **Funding**

558 This study was supported by NIH grant 5R01MH110472 awarded to R.M.M. and G.M.C,  
559 the Memory and Mobility Fund from HudsonAlpha Institute for Biotechnology, and support  
560 from the Pritzker Neuropsychiatric Research Consortium.

561

562 **Acknowledgements**

563 We thank the brain donors and their families without whom this research would not have  
564 been possible. We thank members of the Myers, Cochran, G. Cooper and S. Cooper labs  
565 for many fruitful discussions and input.

566

567 **References**

568 Abramov S, Boytsov A, Bykova D, Penzar DD, Yevshin I, Kolmykov SK, Fridman MV, Favorov AV,  
569 Vorontsov IE, Baulin E, et al. 2021. Landscape of allele-specific transcription factor  
570 binding in the human genome. *Nat Commun* **12**: 2751.

571 Andersen BB, Korbo L, Pakkenberg B. 1992. A quantitative study of the human cerebellum with  
572 unbiased stereological techniques. *J Comp Neurol* **326**: 549–560.

573 Bailey TL, Johnson J, Grant CE, Noble WS. 2015. The MEME Suite. *Nucleic Acids Res* **43**: W39-49.

574 Behrens S, Vingron M. 2010. Studying the evolution of promoter sequences: a waiting time  
575 problem. *J Comput Biol* **17**: 1591–1606.

576 Bioconductor Core Team BPMO [Cre. 2017. TxDb.Hsapiens.UCSC.hg38.knownGene.  
577 <https://bioconductor.org/packages/TxDb.Hsapiens.UCSC.hg38.knownGene> (Accessed  
578 August 23, 2023).

579 Bonham LW, Geier EG, Sirkis DW, Leong JK, Ramos EM, Wang Q, Karydas A, Lee SE, Sturm VE,  
580 Sawyer RP, et al. 2022. *Radiogenomics of C9orf72 expansion carriers reveals global*

581        *transposable element de-repression and enables prediction of thalamic atrophy and*  
582        *clinical impairment.* *Neuroscience*  
583        <http://biorxiv.org/lookup/doi/10.1101/2022.07.28.501897> (Accessed August 11, 2023).

584        Bonham LW, Sirkis DW, Yokoyama JS. 2019. The Transcriptional Landscape of Microglial Genes  
585        in Aging and Neurodegenerative Disease. *Front Immunol* **10**: 1170.

586        Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt RM, Pogson JH, Randle  
587        SJ, Wray S, Lewis PA, Houlden H, et al. 2013. The Parkinson's disease-linked proteins  
588        Fbxo7 and Parkin interact to mediate mitophagy. *Nat Neurosci* **16**: 1257–1265.

589        Carvunis A-R, Rolland T, Wapinski I, Calderwood MA, Yildirim MA, Simonis N, Charlotteaux B,  
590        Hidalgo CA, Barbette J, Santhanam B, et al. 2012. Proto-genes and de novo gene birth.  
591        *Nature* **487**: 370–374.

592        Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R,  
593        Lucas J, Boddie P, Khan A, Manosalva Pérez N, et al. 2022. JASPAR 2022: the 9th release  
594        of the open-access database of transcription factor binding profiles. *Nucleic Acids Res*  
595        **50**: D165–D173.

596        Chen N-C, Solomon B, Mun T, Iyer S, Langmead B. 2021. Reference flow: reducing reference  
597        bias using multiple population genomes. *Genome Biol* **22**: 8.

598        Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, Alföldi J, Watts NA, Vittal C,  
599        Gauthier LD, et al. 2022. *A genome-wide mutational constraint map quantified from*  
600        *variation in 76,156 human genomes.* *Genetics*  
601        <http://biorxiv.org/lookup/doi/10.1101/2022.03.20.485034> (Accessed July 26, 2023).

602        Clifton NE, Hannon E, Harwood JC, Di Florio A, Thomas KL, Holmans PA, Walters JTR, O'Donovan  
603        MC, Owen MJ, Pocklington AJ, et al. 2019. Dynamic expression of genes associated with  
604        schizophrenia and bipolar disorder across development. *Transl Psychiatry* **9**: 74.

605        Conedera S, Apaydin H, Li Y, Yoshino H, Ikeda A, Matsushima T, Funayama M, Nishioka K,  
606        Hattori N. 2016. FBXO7 mutations in Parkinson's disease and multiple system atrophy.  
607        *Neurobiology of Aging* **40**: 192.e1-192.e5.

608        Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Austine-Orimoloye O,  
609        Azov AG, Barnes I, Bennett R, et al. 2022. Ensembl 2022. *Nucleic Acids Res* **50**: D988–  
610        D995.

611        Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwam A, Keane T,  
612        McCarthy SA, Davies RM, et al. 2021. Twelve years of SAMtools and BCFtools.  
613        *Gigascience* **10**: giab008.

614 Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. 2010. Identifying a high  
615 fraction of the human genome to be under selective constraint using GERP++. *PLoS  
616 Comput Biol* **6**: e1001025.

617 Degner JF, Marioni JC, Pai AA, Pickrell JK, Nkadori E, Gilad Y, Pritchard JK. 2009. Effect of read-  
618 mapping biases on detecting allele-specific expression from RNA-sequencing data.  
619 *Bioinformatics* **25**: 3207–3212.

620 Dror I, Golan T, Levy C, Rohs R, Mandel-Gutfreund Y. 2015. A widespread role of the motif  
621 environment in transcription factor binding across diverse protein families. *Genome Res*  
622 **25**: 1268–1280.

623 Emera D, Yin J, Reilly SK, Gockley J, Noonan JP. 2016. Origin and evolution of developmental  
624 enhancers in the mammalian neocortex. *Proc Natl Acad Sci U S A* **113**: E2617-2626.

625 Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A,  
626 Walters GB, Gunnarsdottir S, et al. 2008. Genetics of gene expression and its effect on  
627 disease. *Nature* **452**: 423–428.

628 Garrison E, Sirén J, Novak AM, Hickey G, Eizenga JM, Dawson ET, Jones W, Garg S, Markello C,  
629 Lin MF, et al. 2018. Variation graph toolkit improves read mapping by representing  
630 genetic variation in the reference. *Nat Biotechnol* **36**: 875–879.

631 Ghandi M, Mohammad-Noori M, Ghareghani N, Lee D, Garraway L, Beer MA. 2016. gkmSVM:  
632 an R package for gapped-kmer SVM. *Bioinformatics* **32**: 2205–2207.

633 Gimelbrant A, Hutchinson JN, Thompson BR, Chess A. 2007. Widespread Monoallelic Expression  
634 on Human Autosomes. *Science* **318**: 1136–1140.

635 Groza C, Kwan T, Soranzo N, Pastinen T, Bourque G. 2020. Personalized and graph genomes  
636 reveal missing signal in epigenomic data. *Genome Biol* **21**: 124.

637 GTEx Consortium. 2020. The GTEx Consortium atlas of genetic regulatory effects across human  
638 tissues. *Science* **369**: 1318–1330.

639 Gu Z, Hübschmann D. 2023. rGREAT: an R/bioconductor package for functional enrichment on  
640 genomic regions. *Bioinformatics* **39**: btac745.

641 Hach F, Sarrafi I, Hormozdiari F, Alkan C, Eichler EE, Sahinalp SC. 2014. mrsFAST-Ultra: a  
642 compact, SNP-aware mapper for high performance sequencing applications. *Nucleic  
643 Acids Res* **42**: W494-500.

644 Hiatt SM, Trajkova S, Sebastian MR, Partridge EC, Abidi FE, Anderson A, Ansar M, Antonarakis  
645 SE, Azadi A, Bachmann-Gagescu R, et al. 2023. deleterious, protein-altering variants in  
646 the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental  
647 delay phenotype. *Am J Hum Genet* **110**: 215–227.

648 Huang G, Osorio D, Guan J, Ji G, Cai JJ. 2020. Overdispersed gene expression in schizophrenia.  
649 *NPJ Schizophr* **6**: 9.

650 Iyengar BR, Bornberg-Bauer E. 2023. Neutral Models of De Novo Gene Emergence Suggest that  
651 Gene Evolution has a Preferred Trajectory. *Mol Biol Evol* **40**: msad079.

652 Joseph S, Schulz JB, Stegmüller J. 2018. Mechanistic contributions of FBXO7 to Parkinson  
653 disease. *J Neurochem* **144**: 118–127.

654 Kravitz SN, Ferris E, Love MI, Thomas A, Quinlan AR, Gregg C. 2023. Random allelic expression in  
655 the adult human body. *Cell Reports* **42**: 111945.

656 Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**:  
657 357–359.

658 Lee TI, Young RA. 2013. Transcriptional regulation and its misregulation in disease. *Cell* **152**:  
659 1237–1251.

660 Li H, Feng X, Chu C. 2020. The design and construction of reference pangenome graphs with  
661 minigraph. *Genome Biol* **21**: 265.

662 Loupe JM, Anderson AG, Rizzardi LF, Rodriguez-Nunez I, Moyers B, Trausch-Lowther K, Jain R,  
663 Bunney WE, Bunney BG, Cartagena P, et al. 2023. *Extensive profiling of transcription*  
664 *factors in postmortem brains defines genomic occupancy in disease-relevant cell types*  
665 *and links TF activities to neuropsychiatric disorders*. *Genomics*  
666 <http://biorxiv.org/lookup/doi/10.1101/2023.06.21.545934> (Accessed August 23, 2023).

667 Lun ATL, Smyth GK. 2016. csaw: a Bioconductor package for differential binding analysis of  
668 ChIP-seq data using sliding windows. *Nucleic Acids Res* **44**: e45.

669 Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, Myers Z, Sud P, Jou J, Lin K, et al. 2020.  
670 New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. *Nucleic*  
671 *Acids Res* **48**: D882–D889.

672 Lynch VJ, Nnamani MC, Kapusta A, Brayer K, Plaza SL, Mazur EC, Emera D, Sheikh SZ, Grützner F,  
673 Bauersachs S, et al. 2015. Ancient transposable elements transformed the uterine  
674 regulatory landscape and transcriptome during the evolution of mammalian pregnancy.  
675 *Cell Rep* **10**: 551–561.

676 Marsden CD, Ortega-Del Vecchyo D, O'Brien DP, Taylor JF, Ramirez O, Vilà C, Marques-Bonet T,  
677 Schnabel RD, Wayne RK, Lohmueller KE. 2016. Bottlenecks and selective sweeps during  
678 domestication have increased deleterious genetic variation in dogs. *Proc Natl Acad Sci U*  
679 *S A* **113**: 152–157.

680 Martiniano R, Garrison E, Jones ER, Manica A, Durbin R. 2020. Removing reference bias and  
681 improving indel calling in ancient DNA data analysis by mapping to a sequence variation  
682 graph. *Genome Biol* **21**: 250.

683 McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, Flück P, Cunningham F. 2016. The  
684 Ensembl Variant Effect Predictor. *Genome Biol* **17**: 122.

685 McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G. 2010.  
686 GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* **28**:  
687 495–501.

688 Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RLM, McKenna PJ, Jones PB, Arai  
689 H, Starkey M, et al. 2002. Gene expression analysis in schizophrenia: reproducible up-  
690 regulation of several members of the apolipoprotein L family located in a high-  
691 susceptibility locus for schizophrenia on chromosome 22. *Proc Natl Acad Sci U S A* **99**:  
692 4680–4685.

693 Mizuno A, Okada Y. 2019. Biological characterization of expression quantitative trait loci  
694 (eQTLs) showing tissue-specific opposite directional effects. *Eur J Hum Genet* **27**: 1745–  
695 1756.

696 Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X, Li H,  
697 Kuperwasser N, Ruda VM, et al. 2010. From noncoding variant to phenotype via SORT1  
698 at the 1p13 cholesterol locus. *Nature* **466**: 714–719.

699 Nica AC, Dermitzakis ET. 2013. Expression quantitative trait loci: present and future. *Philos  
700 Trans R Soc Lond B Biol Sci* **368**: 20120362.

701 O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, Rajput B, Robbertse B,  
702 Smith-White B, Ako-Adjei D, et al. 2016. Reference sequence (RefSeq) database at NCBI:  
703 current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res* **44**:  
704 D733-745.

705 Ouyang N, Boyle AP. 2022. *Quantitative assessment of association between noncoding variants  
706 and transcription factor binding*. Bioinformatics  
707 <http://biorxiv.org/lookup/doi/10.1101/2022.11.22.517559> (Accessed July 24, 2023).

708 Papadopoulos C, Callebaut I, Gelly J-C, Hatin I, Namy O, Renard M, Lespinet O, Lopes A. 2021.  
709 Intergenic ORFs as elementary structural modules of de novo gene birth and protein  
710 evolution. *Genome Res* **31**: 2303–2315.

711 Paten B, Novak AM, Eizenga JM, Garrison E. 2017. Genome graphs and the evolution of genome  
712 inference. *Genome Res* **27**: 665–676.

713 Rebeiz M, Tsiantis M. 2017. Enhancer evolution and the origins of morphological novelty. *Curr  
714 Opin Genet Dev* **45**: 115–123.

715 Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. 2019. CADD: predicting the  
716 deleteriousness of variants throughout the human genome. *Nucleic Acids Research* **47**:  
717 D886–D894.

718 Rogers BB, Anderson AG, Lauzon SN, Davis MN, Hauser RM, Roberts SC, Rodriguez-Nunez I,  
719 Trausch-Lowther K, Barinaga EA, Taylor JW, et al. 2023. MAPT expression is mediated by  
720 long-range interactions with cis-regulatory elements. *Genomics*  
721 <http://biorxiv.org/lookup/doi/10.1101/2023.03.07.531520> (Accessed September 26,  
722 2023).

723 Rozowsky J, Abyzov A, Wang J, Alves P, Raha D, Harmanci A, Leng J, Bjornson R, Kong Y,  
724 Kitabayashi N, et al. 2011. AlleleSeq: analysis of allele-specific expression and binding in  
725 a network framework. *Mol Syst Biol* **7**: 522.

726 Rozowsky J, Gao J, Borsari B, Yang YT, Galeev T, Gürsoy G, Epstein CB, Xiong K, Xu J, Li T, et al.  
727 2023. The EN-TEx resource of multi-tissue personal epigenomes & variant-impact  
728 models. *Cell* **186**: 1493-1511.e40.

729 Ruiz-Orera J, Hernandez-Rodriguez J, Chiva C, Sabidó E, Kondova I, Bontrop R, Marqués-Bonet T,  
730 Albà MM. 2015. Origins of De Novo Genes in Human and Chimpanzee. *PLoS Genet* **11**:  
731 e1005721.

732 Schlotterer C. 2015. Genes from scratch--the evolutionary fate of de novo genes. *Trends Genet*  
733 **31**: 215–219.

734 Schubert M, Jónsson H, Chang D, Der Sarkissian C, Ermini L, Ginolhac A, Albrechtsen A,  
735 Dupanloup I, Foucal A, Petersen B, et al. 2014. Prehistoric genomes reveal the genetic  
736 foundation and cost of horse domestication. *Proc Natl Acad Sci U S A* **111**: E5661-5669.

737 Smith RM, Webb A, Papp AC, Newman LC, Handelman SK, Suhy A, Mascarenhas R, Oberdick J,  
738 Sadee W. 2013. Whole transcriptome RNA-Seq allelic expression in human brain. *BMC  
739 Genomics* **14**: 571.

740 Splinter E, Heath H, Kooren J, Palstra R-J, Klous P, Grosveld F, Galjart N, de Laat W. 2006. CTCF  
741 mediates long-range chromatin looping and local histone modification in the beta-globin  
742 locus. *Genes Dev* **20**: 2349–2354.

743 Stevenson KR, Coolon JD, Wittkopp PJ. 2013. Sources of bias in measures of allele-specific  
744 expression derived from RNA-sequence data aligned to a single reference genome. *BMC  
745 Genomics* **14**: 536.

746 Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, Taliun SAG, Corvelo A, Gogarten  
747 SM, Kang HM, et al. 2021. Sequencing of 53,831 diverse genomes from the NHLBI  
748 TOPMed Program. *Nature* **590**: 290–299.

749 Zhao G. 2023. Shared and disease-specific glial gene expression changes in neurodegenerative  
750 diseases. *Nat Aging* **3**: 246–247.

751 2010. *R a language and environment for statistical computing: reference index*. R Foundation  
752 for Statistical Computing, Vienna.

753